Researchers studying pleural mesothelioma have identified a possible relationship between loss of the MTAP gene, the immune environment within tumors, and responses to immune-checkpoint inhibitor treatment. The findings, published November 6, 2026, in Clinical Cancer Research, could help guide future work on why some patients respond to immunotherapy while others do not.
The study does not establish MTAP loss as a clinically validated test for choosing mesothelioma treatment. Its findings are associations that require additional research.
What did researchers investigate?
The investigators examined two independent groups of patients with malignant pleural mesothelioma. A discovery group at Japan's National Cancer Center Hospital included 52 patients whose tumor samples were available for whole-genome and RNA sequencing. The researchers also examined findings in a nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort.
The analysis considered genetic alterations, patterns of gene activity, immune cells within tumors, and the diversity of T-cell receptors—features that may help explain how the immune system recognizes cancer.
What did the study find?
Among patients treated with immune-checkpoint inhibitors, the overall response rates reported in the published abstract were 30% in the sequencing cohort and 29.4% in the C-CAT cohort. These are response rates among treated patients in the analyzed groups, not a comparison proving that MTAP loss caused those responses.
Patients whose tumors responded to immunotherapy tended to show greater diversity of T-cell receptors, more CD8-positive T cells within the tumor, and enrichment of M1 macrophages. These findings suggest a more immune-active tumor environment.
MTAP loss was associated with greater CD8-positive T-cell infiltration and T-cell-receptor diversity. In the C-CAT cohort, it was also linked with a higher rate of response to immune-checkpoint inhibitors. By contrast, alterations involving BAP1 and NF2 did not show consistent associations with the immune features or immunotherapy efficacy examined in this analysis.
Why does MTAP matter in mesothelioma?
MTAP is a gene involved in cellular metabolism. Some mesothelioma tumors have lost MTAP function. Researchers are investigating whether that loss may reveal characteristics of the tumor that are useful for understanding disease biology or identifying future treatment approaches.
This new study examines MTAP loss as a possible marker of response to immunotherapy. That is a different question from whether an experimental medicine can directly exploit a metabolic weakness in MTAP-deficient cancer cells.
H&S previously reported on the SELECTmeso1 trial of an MTAP-targeted treatment. The November 6 research should not be interpreted as evidence that such targeted medicines work, or that MTAP testing currently determines who should receive checkpoint inhibitors.
Does this change treatment decisions today?
No immediate change in treatment selection follows from these results. The investigators describe MTAP loss as a candidate biomarker that warrants further study. A candidate biomarker is a biological feature that may prove useful after larger, appropriately designed studies confirm its predictive value.
The abstract does not establish that patients with MTAP loss live longer on immunotherapy, nor does it show that MTAP status alone can reliably predict an individual patient's benefit. It would be premature to recommend starting, stopping, or choosing a treatment based on this finding.
Patients with pleural mesothelioma should discuss treatment options and any tumor-testing results with their oncology team. Decisions depend on the patient's diagnosis, medical history, disease characteristics, and available evidence—not a single emerging research association.
What questions remain?
Future studies will need to determine whether the association can be reproduced across larger and more diverse patient populations, whether MTAP status adds useful predictive information beyond other tumor characteristics, and whether it helps distinguish immunotherapy benefit from general differences in prognosis.
The new research is meaningful because it points toward a more individualized understanding of mesothelioma treatment. But it is an early research finding, not a new approved therapy, diagnostic standard, or treatment guideline.
Original research and related H&S resources
- Tateishi and colleagues, Clinical Cancer Research, published November 6, 2026 (PMID 42993171)
- Original journal article, DOI 10.1158/1078-0432.CCR-26-1855
- H&S: Mesothelioma treatment options
- H&S: Earlier MTAP-targeted treatment trial report
Research scope: This report is based on the peer-reviewed publication's publicly available abstract; detailed full-text analyses were not independently reviewed. Medical information notice: Humpleby & Strauss, P.C. is a law firm and does not provide medical treatment or individualized medical advice. Research associations do not establish individual prognosis or treatment suitability. Consult a qualified mesothelioma specialist for medical decisions. Editorial standards.